Hydroxyzine is a first-generation antihistamine that is commonly used for the treatment of various allergic conditions such as hives and itching.

Fentanyl, a tiny molecule drug, is a COX-2 inhibitor that specifically targets the COX-2 enzyme causing inflammation and pain.

Opdivo® (nivolumab) and CABOMETYX® (cabozantinib) Show Long-Term Survival in 4-Year CheckMate-9ER Trial for 1st-Line Advanced RCC.

Meloxicam, a small molecule drug, is a COX-2 inhibitor that targets the enzyme causing inflammation and pain.

Scholar Rock Reveals U.S. FDA Approval for Phase 2 Trial Commencement, Testing Apitegromab for Obesity Management.

Cyclobenzaprine is a drug opposing ADRA2, 5-HT2A, and H1 receptors, approved to treat muscle spasticity, fibromyalgia, stress disorders, back pain, and both active and post-COVID-19 symptoms.

Gabapentin is a small molecule drug developed by Pfizer that functions as a CACNA2D2 and Cav2.2 blocker.

Sanofi intends to buy Inhibrx, Inc., bringing a promising rare disease candidate targeting Alpha-1 Antitrypsin Deficiency into its portfolio.

Strand Therapeutics recently revealed that the FDA has approved its request to commence a Phase 1 clinical trial, marking the initial human study of STX-001.

Gilead Sciences' EVOKE-01 Phase 3 Trial for Metastatic NSCLC Fails to Achieve Primary Endpoint: A Comparison of Trodelvy and Docetaxel.

Sandoz Finalizes USD 170 Million Purchase of Coherus BioSciences' Biosimilar Drug CIMERLI* (ranibizumab-eqrn) in the US

BioNTech and DualityBio have launched a critical Phase 3 study for their therapeutic agent BNT323/DB-1303, targeting advanced breast cancer.